Updated:
National Foundation for Cancer Research
Founded in 1973 by Franklin C. Salisbury, Sr. following the loss of his child to leukemia, the National Foundation for Cancer Research channels...
National Foundation for Cancer Research
Founded in 1973 by Franklin C. Salisbury, Sr. following the loss of his child to leukemia, the National Foundation for Cancer Research channels unrestricted donor capital directly to academic scientists pursuing fundamental cancer biology. The foundation explicitly avoids clinical trials, instead funding the basic molecular and cellular research that can later become therapeutic targets. Salisbury, Sr. structured NFCR as a publicly supported charity, a model his son Franklin, Jr. continues as CEO. NFCR's grantmaking focuses on cross-disciplinary early-stage research in oncology, genomics, immunology, and cancer metabolism. The foundation's model relies on multi-year, unrestricted awards to individual principal investigators, allowing researchers to pivot when promising pathways emerge. Funded scientists have included pioneers recognized with major international prizes. NFCR concentrates its deployment in North America, Europe, and Asia, supporting laboratories at universities in the United States, the United Kingdom, China, and Japan. Collaborative research centers established in partnership with NFCR include laboratories at the University of Oxford and the Suzhou Institute for Advanced Research, connecting Western and Asian oncology research networks. NFCR has deployed over $400 million in cumulative cancer research funding since inception. The organization operates from Rockville, Maryland, and reports a working board of scientists and business leaders who vet grantees through peer review. In May 2024, NFCR announced a partnership with the AIM-HI Accelerator Fund, committing co-investment capital to oncology startups emerging from NFCR-funded basic research programs, marking a bridge toward translational application. The foundation also runs public education campaigns on cancer prevention and hosts an annual scientific summit. Structurally, NFCR differs from large institutional cancer funders by targeting the gap between initial scientific curiosity and institutional grants. Most peer foundations fund late-stage clinical trials or patient advocacy; NFCR exclusively supports the benchtop stage, absorbing the risk that established grantmakers avoid. This positioning places it functionally closer to a scientific discovery incubator than a traditional health charity.
General information
Firm type
Foundation
Year founded
1973
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Rockville
Corporate office
Rockville, MD, United States
Principals
Franklin C. Salisbury, Jr.
Chief Executive Officer
Sector focus
Frequently asked questions
How does the National Foundation for Cancer Research source the scientists it funds?
NFCR uses a peer-review system managed by a scientific advisory board of active cancer researchers. The foundation identifies individual principal investigators whose work targets fundamental molecular mechanisms of cancer, then awards multi-year unrestricted grants that allow the researcher to follow promising leads without the administrative burden of reapplying annually. Nomination, review, and renewal decisions are made by working scientists rather than program officers.
Does NFCR fund clinical trials or patient care?
No. NFCR exclusively funds basic laboratory research — the cellular, molecular, and genomic science that precedes drug development. The organization explicitly does not fund clinical trials, patient treatment programs, or hospital infrastructure. Its mandate ends at the laboratory door, leaving translational and clinical work to other funders and biopharma partners.
What separates NFCR's grantmaking model from the NIH or American Cancer Society?
NFCR awards unrestricted grants; the researcher decides how to allocate funds within the scope of the proposed work, and can reallocate resources mid-grant when experimental results open a new direction. By contrast, NIH RO1 and ACS grants are typically restricted to pre-specified aims with limited flexibility. NFCR also targets earlier-stage, higher-risk hypotheses that might struggle to meet the preliminary-data requirements of institutional grantmakers.
Who makes investment and grant decisions at the organization?
Franklin C. Salisbury, Jr. serves as CEO and has day-to-day operational authority. Grant allocations are recommended by NFCR's scientific advisory board through peer review and approved by the board of directors. Investment management for the endowment is overseen by the board's finance committee, whose membership is drawn from business leadership and finance professions.
Is NFCR a private foundation or a public charity?
NFCR is a 501(c)(3) public charity, supported by donations from individuals and corporations. It is not the philanthropic vehicle of a single family or fortune, nor does it operate as a private foundation with a single funding source. The organization files IRS Form 990 and reports its grants publicly.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: